

# Join IQVIA at Virtual ISPOR Europe 2021

*Real world evidence. Real HEOR and market access expertise. Real results.*

IQVIA's real world evidence experts will be contributing to a range of events at Virtual ISPOR Europe 2021, **30 November–3 December**.

Join us to discover new insights from our live and on-demand panel contributions, and more than 50 posters featuring our research.



## ISPOR forum

### 207FR • Linking HTA and Procurement: Forum Discussion on Assessing the Value of Medical Devices – ISPOR SIG MD&D KEY Project Presentation

*Moderator:* Arthi Chandran, MS, MPH, DPH, Becton Dickinson Medical Devices, USA

*Speakers:* Michael Cangelosi, MA, MPH, Boston Scientific Corporation, USA; Akriti Chahar, MA, PhD Scholar, IQVIA, India; Simon Eggington, MSc, Medtronic International Trading Sarl, Switzerland

• Wednesday, 1 December • 12:30-13:30



## Issue panels

### 205IP • The PRO-CTCAE to Understand Symptomatic Toxicities with Cancer Medication: An American Dream or a Global Opportunity?

*Moderator:* Matthew Reaney, CPsychol, CSci, MSc, IQVIA, UK

*Panelists:* Olivier Chassany, MD, PhD, Patient-Centered Outcomes Research, University Paris-Diderot, France; Perminder Dhillon, MD, Royal Surrey Hospital NHS Foundation Trust, UK; Eva Dietrich, Pharmacist Prof. Dr. rer. Nat. MSc, University of Bonn Pharmaceutical Institute, Germany

• Wednesday, 1 December • 12:30-13:30

### 402IP • Realising the Potential of Real World Data and Evidence: How Can Pharmaceutical Companies Optimise through Capabilities, Structure and Governance?

*Moderator:* Callum Caldwell, BSc, IQVIA, UK

*Panelists:* John Cai, MD, Merck, USA; Maurille Feudjo Tepie, Msc. PhD, Amgen Ltd, UK; Paul Petraro, ScD, MPH, Boehringer Ingelheim Pharmaceuticals Inc., USA

• Friday, 3 December • 11:00-12:00



## On-demand podium sessions

### P27 • Vaccination Coverage Trends for Hepatitis B in Infants from the Brazilian and Colombian Expanded Immunization Program: A Real-World Analysis of COVID-19 Pandemic Impact

*Pedro Lima, Ariane Abreu, Fabián Hernández, Johnny Martins, Bruce Kano, Diego Kashiura, Guilherme Julian*

• Monday, 22 November • 16:30-16:45

### P50 • Competing Risk and Multistate Model Compared to Partitioned Survival Model in Metastatic Non-Small Cell Lung Cancer

*Antione Le Mezo, Marguerite Kandel, Mégane Caillon, Jean Vannak Chauny, Isabelle Borget*

• Monday, 22 November • 16:15-16:30

### P74 • Treatment Patterns and Outcomes in Patients with Acute Myeloid Leukaemia (AML) in England: A Cancer Analysis System (CAS) Registry Retrospective Cohort Study

*Sophie Caseby, Holly Cranmer, Vanessa Ohlmeyer, Jayne Groucott, Jack Eaton, Tanja Podkonjak, Alexandrina Lambova, Elizabeth Adamson, Isabella Kearns*

• Monday, 22 November • 16:15-16:30

*All times are in Central European Time (CET) (UTC-5)*



These virtual activities will be available on demand until 2 January 2022. [Click here](#) to access.

# Posters

## GENERATING THE RIGHT EVIDENCE

Explore in our posters at Virtual ISPOR Europe 2021 how we are applying rigorous, innovative approaches to seamlessly integrate unparalleled data assets and best-in-class technology-enabled analytics to deliver representative, relevant results of benefits, risks and outcomes across a range of topics and therapy areas.

### VIRTUAL POSTER DISCUSSION SESSION 1: TUESDAY, 30 NOVEMBER 2021

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	POSA30	CANADIAN REAL-WORLD EXPERIENCE WITH NIVOLUMAB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH SYSTEMIC ANTICANCER THERAPY <b>Disease/disorder: Oncology</b>	Carroll R, Bortolini M, Calleja A, Munro R, Kong S, Daumont MJ, Penrod JR, Lacoïn L, Cheung WY
ECONOMIC EVALUATION	POSA84	BUDGET IMPACT OF LAROTRECTINIB FOR NTRK FUSION POSITIVE SOLID TUMORS IN GREECE <b>Disease/disorder: Oncology</b>	Kontoudis I, Kalogeropoulou M
	POSA97	ASSESSMENT OF THE ECONOMIC IMPACT IN RELATION WITH THE USE OF SUGAMMADEX IN THE FRENCH HOSPITALS SETTING <b>Disease/disorder: Drugs, Surgery</b>	Raft J, Anastasy C, Saillio E, Mackosso C, Vega V, Le Dissez C, Alfonsi P
	POSA110	COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN (BV) IN ADULT AND PAEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA IN FRANCE <b>Disease/disorder: Oncology</b>	Minacori R, Apert M, Leproust S, Monnier R, Casasnovas RO, Brice P, Borse RH, Gandhi J, Rai A
	POSA128	COST-EFFECTIVENESS ANALYSIS OF AVELUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE AS A FIRST-LINE (1L) MAINTENANCE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN TAIWAN <b>Disease/disorder: Oncology, Urinary/Kidney Disorders</b>	Chang WC, Xiao Y, Lin AY, Su PJ, Goh C, Wu E, Liu K, Chou P, Kuo K, Palencia R, Chang J, Kearney M, Kapetanakis V, Benedict A
EPIDEMIOLOGY & PUBLIC HEALTH	POSA177	REAL-WORLD PROFILING OF NON-SMALL CELL LUNG CANCER PATIENTS IN JAPAN <b>Disease/disorder: Drugs, Oncology</b>	Chang Takahashi E, Wakase S, Ito M, Taylor T
	POSA190	SOCIO-ECONOMIC INFLUENCES ON COUNTY-LEVEL DIFFERENCES IN COVID-19 INCIDENCE DURING THE SECOND WAVE IN GERMANY <b>Disease/disorder: Infectious Disease (non-vaccine)</b>	Gossmann JA, Meier C, Greiner RA, Otto J, Shlaen E, Batscheider A
	POSA196	ECONOMIC BURDEN ASSOCIATED WITH ADVANCED PROSTATE CANCER IN MEXICO <b>Disease/disorder: Oncology</b>	Saturnino LTM, Polanco A, Kuperman G, Gasca R, Larrosa J
HEALTH SERVICE DELIVERY & PROCESS OF CARE	POSA236	REAL-WORLD TREATMENT (TX) CHARACTERISTICS FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSLC) WITHOUT ACTIONABLE MUTATIONS AFTER INTRODUCTION OF IMMUNE CHECKPOINT INHIBITORS (ICIS) IN EU4 AND UK <b>Disease/disorder: Oncology</b>	Multani J, Casey V, Mpima S, Yasuda M, Chen CC, Manuguid F, Kalilani L, Giove TJ, Chao J, Aziez A, Stojadinovic A, Hogeia C
	POSA249	DIAGNOSTIC PATHWAYS, GENETIC TESTING, AND IMPACT OF COVID-19 ON PATIENTS IN EUROPE WITH X-LINKED RETINITIS PIGMENTOSA: RESULTS FROM THE CROSS-SECTIONAL EXPLORE XLRP 1 PHYSICIAN SURVEY <b>Disease/disorder: No Specific Disease</b>	Denee T, Pungor K, Kambarov Y, Nissinen R, Lee J, Ampeh K, Parmeggiani F
HEALTH TECHNOLOGY ASSESSMENT	POSA264	REIMBURSABLE HEALTHCARE APPS (DIGA) IN GERMANY: WHICH FACTORS IMPACT THE BFARM'S2 ASSESSMENT OUTCOME AND A DIRECTORY LISTING? <b>Disease/disorder: No Specific Disease</b>	Drews J, Schuller JM, Kuschel AS, Biessenberger A, Bonduelle D
	POSA265	HTA REQUIREMENTS FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN GERMANY <b>Disease/disorder: No Specific Disease</b>	Dose J, Eheberg D, Hinnenthal M, Schuh I, Unterweger A, Bonduelle D
	POSA280	USING ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO INFORM EVIDENCE DEVELOPMENT FOR OPTIMISING HTA OUTCOMES IN EUROPE <b>Disease/disorder: Multiple Diseases, Oncology</b>	Shankar R, Fonseca Santos F, Strübing A, Martin L, Exenberger A, Halmos T, Capretto L, Feng G, Rosenlund M

[Click here](#) for further details of posters available on the Virtual ISPOR Europe 2021 website

**VIRTUAL POSTER DISCUSSION SESSION 1: TUESDAY, 30 NOVEMBER 2021 continued**

TOPIC	CODE	TITLE	AUTHORS
HEALTH TECHNOLOGY ASSESSMENT continued	POSA284	ASSESSMENT OF SELECT HER2-NEGATIVE MBC AGENTS AS A PROXY TO UNDERSTAND HTAB UNCERTAINTIES IN HER2-LOW MBC AGENTS IN EU4 AND ENGLAND <b>Disease/disorder: Oncology</b>	de Milliano T, Harding T, Seddik A, Oddsdottir J, Schmid P, Anastasaki E
	POSA286	EARLY EXPERIENCE WITH HEALTH TECHNOLOGY ASSESSMENTS FOR COVID-19 TREATMENTS <b>Disease/disorder: Cardiovascular Disorders, Infectious Disease (non-vaccine), Respiratory-Related Disorders</b>	Sitavu-Radu X, Tulika T, Rajani R, Vasileva S
METHODOLOGICAL & STATISTICAL RESEARCH	POSA306	RECOMMENDED APPROACHES FOR ANALYZING CLINICAL OUTCOMES ASSESSMENT DATA FROM ONCOLOGY TRIALS FOR DIFFERENT STAKEHOLDERS <b>Disease/disorder: Oncology</b>	Stull D, Griffiths P, Reaney M, Barnes G
PATIENT-CENTERED RESEARCH	POSA332	PATIENT REPORTED EXPERIENCE MEASURE FOR ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) IN GREECE <b>Disease/disorder: Rare and Orphan Diseases</b>	Markouri A, Tripsa T, Vareli K, Papastefanou V

**VIRTUAL POSTER DISCUSSION SESSION 2: WEDNESDAY, 1 DECEMBER 2021**

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	POSB13	THIRTY-DAY READMISSION IN US HOSPITALIZED COVID-19 PATIENTS <b>Disease/disorder: Infectious Disease (non-vaccine)</b>	Mozaffari E, Liang S, Stewart HM, Thrun M, Hodgkins P, Haubrich R
ECONOMIC EVALUATION	POSB74	BELANTAMAB MAFODOTIN AS THE FIRST-IN-CLASS ANTI-BCMA TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A BUDGET IMPACT AND COST-EFFECTIVENESS ANALYSIS <b>Disease/disorder: Biologics and Biosimilars, Oncology, Rare and Orphan Diseases</b>	Speranza G, Diliberto MJ, Fattore C, Fiorentino F, Prawitz T, Nikolaou A, Samele R
	POSB90	HEALTHCARE RESOURCE UTILIZATION AND COSTS IN ADULT PATIENTS WITH SPASTICITY: A MATCHED COHORT ANALYSIS <b>Disease/disorder: Neurological Disorders</b>	Hull M, Anupindi VR, He J, Danchenko N, DeKoven M, Bouchard J
	POSB128	THE CLINICAL & ECONOMIC BURDEN OF TREATMENT RESISTANT DEPRESSION IN THE GCC: THE KINGDOM OF SAUDI ARABIA, KUWAIT AND THE UNITED ARAB EMIRATES <b>Disease/disorder: Mental Health</b>	Akram A, Al-Sabahy M, Al Jedai A, Al-Mudaiheem H, Farghaly M, Fallata E, Alibrahim O, Shoukry T, Basu S, Chalouhi D, Elsharkawy A, Mohamed O
	POSB129	COST-EFFECTIVENESS ANALYSIS OF UPADACITINIB AS A TREATMENT OPTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS IN KINGDOM OF SAUDI ARABIA <b>Disease/disorder: Musculoskeletal Disorders</b>	Al-Abdulkarim HA, Almodaimegh H, Abu Esba LC, Sharma Y, Attar S, Hussain W, Alhomoed I, Al-Omari BA, Mohamed O, Alsaqa'aby M, Roshdy A, Anwar A, Hamad T, Alzahrani Z
	POSB130	INTRODUCTION OF DUPILUMAB TO THE EXISTING TREATMENT OPTIONS FOR MANAGEMENT OF TYPE II INFLAMMATORY DISEASES IN THE KINGDOM OF SAUDI ARABIA: BUDGET IMPACT ANALYSIS <b>Disease/disorder: Multiple Diseases, Respiratory-Related Disorders, System Disorders/Conditions</b>	Alrumaih A, Al Mohaideb M, Alhayan H, Zaitoni M, Marglani O, Bulkhi A, Sharma Y, Patil S, Sreedharan S, Mohamed O, Al-Abdulkarim HA
	POSB135	BUDGET IMPACT ANALYSIS OF BRIGATINIB FOR FIRST-LINE TREATMENT OF ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ITALY <b>Disease/disorder: Drugs, Oncology</b>	Urbinati D, La Malfa P, Demma F, Viti R, Cranmer H, Hernandez LG
	POSB157	DEMOGRAPHICS AND TREATMENT PATTERNS OF ONYCHOMYCOSIS PATIENTS CLAIMING EFINACONAZOLE: A CANADIAN RETROSPECTIVE CLAIMS ANALYSIS STRATIFIED BY DIABETES STATUS <b>Disease/disorder: Diabetes/Endocrine/Metabolic Disorders, Drugs, Sensory System Disorders</b>	Yang H, Kukaswadia A, Gaudet V, Sharma A, Barbeau M
EPIDEMIOLOGY & PUBLIC HEALTH	POSB174	CLINICAL AND ECONOMIC IMPACT OF NON-PHARMACOLOGICAL INTERVENTIONS ON THE COVID-19 PANDEMIC: A PREDICTIVE MODEL BASED ON THE SPANISH CASE <b>Disease/disorder: Infectious Disease (non-vaccine)</b>	Viayna E, Candel FJ, Callejo-Velasco D, Ramos R, San-Roman J, Barreiro P, Carretero MDM, Kolipinski A, Canora J, Zapatero A, Runken MC
	POSB191	MODELED IMPACT OF NIRSEVIMAB AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV) AMONG FRENCH INFANTS EXPERIENCING THEIR FIRST RSV SEASON <b>Disease/disorder: Pediatrics, Respiratory-Related Disorders, Vaccines</b>	Beuvelet M, Hoestlandt C, Lemaitre M, Demont C, Kieffer A

[Click here](#) for further details of posters available on the Virtual ISPOR Europe 2021 website

**VIRTUAL POSTER DISCUSSION SESSION 2: WEDNESDAY, 1 DECEMBER 2021 continued**

TOPIC	CODE	TITLE	AUTHORS
EPIDEMIOLOGY & PUBLIC HEALTH continued	POSB193	COVID-19 VACCINE DEVELOPMENT PIPELINE: 2021 <b>Disease/disorder: Vaccines</b>	Ahlawat R, Singhal R, Rajput A, Goyal R
	POSB197	IMPACT OF IMMUNE CHECKPOINT INHIBITORS (ICIS) ON THE MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN REAL-WORLD PRACTICE AT KAROLINSKA UNIVERSITY HOSPITAL, STOCKHOLM BETWEEN 2012 AND 2018 <b>Disease/disorder: Oncology</b>	Ekman S, Brustugun OT, Sørensen JB, Kejs AM, Ann Q, Bortolini M, Calleja A, Rosengren L, Huetson P, Daumont MJ, Penrod JR, Jacobs HC, Lacoïn L, Koyi H
HEALTH SERVICE DELIVERY & PROCESS OF CARE	POSB236	X-LINKED RETINITIS PIGMENTOSA NEGATIVELY AFFECTS PATIENTS' WORK STATUS, INDEPENDENCE, AND QUALITY OF LIFE: RESULTS FROM THE CROSS-SECTIONAL EXPLORE XLRP 1 PHYSICIAN SURVEY <b>Disease/disorder: Rare and Orphan Diseases</b>	Lee J, Pungor K, Kambarov Y, Nissinen R, Deneë T, Ampeh K, Parmeggiani F
	POSB241	A RETROSPECTIVE STUDY OF THE MANAGEMENT OF ANAEMIA IN PATIENTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE IN FRANCE: THE AMACK STUDY <b>Disease/disorder: Urinary/Kidney Disorders</b>	Choukroun G, Courivaud C, Rostoker G, Zaoui P, Menoyo V, Harmand S, Dubel L, Lorenzo MM
HEALTH TECHNOLOGY ASSESSMENT	POSB267	INFLUENCE OF REAL-WORLD EVIDENCE TO SUPPORT SINGLE ARM TRIALS SUBMITTED TO NICE FOR ORPHAN ONCOLOGY PRODUCTS <b>Disease/disorder: Multiple Diseases</b>	Falla E, Gaultney J
	POSB272	USE OF REAL-WORLD EVIDENCE FOR REIMBURSEMENT IN BRAZILIAN PUBLIC SECTOR: AN ANALYSIS OF SUBMISSIONS IN NEUROLOGY AND RHEUMATOLOGY <b>Disease/disorder: Neurological Disorders</b>	Meirelles I, Kano B, Martins J, Kashiura D, Julian G, Lemos L, Lima P, Oesterreicher B, Tôrres L
MEDICAL TECHNOLOGIES	POSB293	THE EXPERIENCE OF AN OUTSOURCED COMPREHENSIVE GENOMIC PROFILING SERVICE IN ITALY <b>Disease/disorder: Oncology</b>	Viviani Anselmi C, Cipelli R, Heiman F, Lugini A, Montrone M, Pagni F, Avitabile A, D'Ambrogio A, Lattanzi L
METHODOLOGICAL & STATISTICAL RESEARCH	POSB318	EVALUATION OF ASYNCHRONOUS ONLINE FOCUS GROUPS FOR USE IN QUALITATIVE STUDIES AROUND PATIENT EXPERIENCE DATA <b>Disease/disorder: No Specific Disease</b>	Hunter M, Reaney M, Bean SE
REAL WORLD DATA & INFORMATION SYSTEMS	POSB392	UNDERSTANDING THE SECONDARY CARE CHARACTERISTICS AND PATHWAYS OF MULTIPLE MYELOMA PATIENTS WHO REACH SECOND-LINE THERAPY USING THE HOSPITAL EPISODE STATISTICS (HES) DATABASE <b>Disease/disorder: Oncology</b>	Mary Babu E, Fermahan S, Chavda S, Chetty M, Navani S, Matthew A, Hudson R
STUDY APPROACHES	POSB425	METHODOLOGICAL CHALLENGES TO CORONAVIRUS DISEASE (COVID-19) EVIDENCE GENERATION TO INFORM HEALTH TECHNOLOGY ASSESSMENT (HTA) <b>Disease/disorder: Respiratory-Related Disorders</b>	Rtveladze K, Gaultney J, Crossman-Barnes CJ, Kamra S, Wright D

**VIRTUAL POSTER DISCUSSION SESSION 3: THURSDAY, 2 DECEMBER 2021**

TOPIC	CODE	TITLE	AUTHORS
CLINICAL OUTCOMES	POSC26	PREFERENCES TOWARD ATTRIBUTES OF DISEASE-MODIFYING THERAPIES: THE ROLE OF NURSES IN MULTIPLE SCLEROSIS CARE (DECISIONS-MS STUDY) <b>Disease/disorder: Neurological Disorders</b>	Muñoz B, Medrano N, Azanza-Munárriz C, Becerril-Ríos N, Goicochea-Briceño H, Horro R, Lendínez-Mesa A, Sánchez-Franco C, Álvarez C, Carreño Á, Sarmiento M, Bueno-Gil G, Maurino J
ECONOMIC EVALUATION	POSC96	BUDGET IMPACT ANALYSIS FOR INTRODUCTION OF CLADRIBINE TABLETS AS A TREATMENT FOR HIGH DISEASE ACTIVE RELAPSING MULTIPLE SCLEROSIS IN UAE <b>Disease/disorder: Neurological Disorders</b>	Inshasic J, Yamout B, Farghali M, Sara Ahmad MA, Alcharif R, Almadani A, Basu S, Boshra A, Hassan AM, Moussa A, El Ojeil R, Shakra M, Shatila A, Thakre M, Verma A, Zein T
	POSC100	HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PEDIATRIC CEREBRAL PALSY PATIENTS WITH SPASTICITY: A MATCHED COHORT ANALYSIS <b>Disease/disorder: Neurological Disorders</b>	Hull M, Anupindi R, He J, Danchenko N, DeKoven M, Bouchard J
	POSC101	HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH CERVICAL DYSTONIA <b>Disease/disorder: Neurological Disorders</b>	Hull M, Anupindi R, He J, Danchenko N, DeKoven M, Bouchard J
	POSC104	DETERMINING COST DATA FOR FERTILITY TREATMENT IN A SPANISH SETTING <b>Disease/disorder: Reproductive and Sexual Health</b>	Roeder C, Lukyanov V, de Agustin Calvo E, Schwarze JE

[Click here](#) for further details of posters available on the Virtual ISPOR Europe 2021 website

**VIRTUAL POSTER DISCUSSION SESSION 3: THURSDAY, 2 DECEMBER 2021 continued**

TOPIC	CODE	TITLE	AUTHORS
ECONOMIC EVALUATION continued	POSC109	COST-EFFECTIVENESS ANALYSIS OF REFERENCE RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE ALFA (R-HFSH-ALFA) AND URINARY HIGHLY PURIFIED MENOPAUSAL GONADOTROPIN (HMG-HP) BASED ON DATA FROM A LARGE GERMAN REGISTRY <b>Disease/disorder: Reproductive and Sexual Health</b>	Bühler K, Roeder C, Schwarze JE, Lispi M, Allignol A, D'Hooghe T, Falla E, Lukyanov V, Fischer R
	POSC152	COST-EFFECTIVENESS ANALYSIS OF FOLLITROPIN ALFA PRODUCT (GONAL-F) COMPARED TO ITS BIOSIMILARS BASED ON META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS <b>Disease/disorder: Reproductive and Sexual Health</b>	Lukyanov V, Falla E, de Agustin Calvo E, Schwarze JE, D'Hooghe T, Roeder C
EPIDEMIOLOGY & PUBLIC HEALTH	POSC193	ECONOMIC BURDEN ASSOCIATED TO ACUTE MYELOID LEUKEMIA IN MEXICO <b>Disease/disorder: Oncology, Personalized and Precision Medicine, Rare and Orphan Diseases</b>	Saturnino LTM, Kuperman G, Gasca R, Larrosa J, Zapata N, Polanco A
	POSC200	DISPARITIES AND TRENDS OF COVID-19 EPIDEMIOLOGY IN EU-5 COUNTRIES ACROSS PANDEMIC WAVES: A TARGETED LITERATURE REVIEW (TLR) <b>Disease/disorder: Infectious Disease (non-vaccine)</b>	Kamra S, Venkateswara Rao J, Chidirala S, Pagidigumula R, Hyderboini R, Mandlik R, Dabral S, Sirumalla Y
HEALTH POLICY & REGULATORY	POSC205	A EUROPEAN PERSPECTIVE ON CHALLENGES AND OPPORTUNITIES FOR SMART PENS IN DIABETES CARE <b>Disease/disorder: Diabetes/Endocrine/Metabolic Disorders</b>	Exenberger A, Parry L, Anastasaki E
HEALTH TECHNOLOGY ASSESSMENT	POSC253	ANALYSIS OF RESULT OF EARLY BENEFIT ASSESSMENT AND REIMBURSEMENT PRICE AFTER FREE-PRICING PERIOD IN GERMANY <b>Disease/disorder: No Specific Disease</b>	Batscheider A, Shlaen E, Rich A, Strimitzer K, Greiner RA
	POSC261	HOW WAS THE SOCIETAL PERSPECTIVE ADDRESSED IN HTA DECISIONS ABOUT ALZHEIMER'S DISEASE? <b>Disease/disorder: Neurological Disorders</b>	Törres L, Martins J, Kashiura D, Oesterreicher B, Lemos L, Lima P, Kano B, Meirelles I, Julian G
	POSC262	EXPLORING HEALTH TECHNOLOGY ASSESSMENT (HTA) ACCEPTANCE OF DISEASE-FREE SURVIVAL (DFS) AS AN APPROPRIATE ENDPOINT IN EARLY-STAGE, NON-METASTATIC SOLID TUMOURS <b>Disease/disorder: Oncology</b>	Constandse T, Wagner P, Bainor A, Fisher C, Ryan J
	POSC273	HAS IQWIG'S 15% RESPONSE THRESHOLD MADE A MINIMALLY IMPORTANT DIFFERENCE TO BENEFIT ASSESSMENTS? <b>Disease/disorder: No Specific Disease</b>	Kruger R, Strydom M, Wagner P, van Engen A
	POSC279	THE IMPACT OF A REASSESSMENT DUE TO NEW SCIENTIFIC FINDINGS ON THE ADDITIONAL BENEFIT AND ON THE REIMBURSED PRICE OF PHARMACEUTICAL PRODUCTS ACCORDING TO §35A SGB V IN GERMANY <b>Disease/disorder: Diabetes, Endocrine/Metabolic Disorders, Oncology</b>	Schmalhofer C, Ernst I, Fischer T, Strimitzer K, Bonduelle D
PATIENT-CENTERED RESEARCH	POSC330	QUALITY OF LIFE IN PATIENTS WITH GAUCHER DISEASE <b>Disease/disorder: Diabetes, Endocrine/Metabolic Disorders</b>	Sethi A, Thode R, Rawat NS, Goyal R
	POSC355	MEASURING THE EXPERIENCE OF LIVING WITH SPINAL MUSCULAR ATROPHY: THE ROLE OF THE SMA INDEPENDENCE SCALE <b>Disease/disorder: Neurological Disorders, Rare and Orphan Diseases</b>	Vazquez JF, brañas Pampillon M, Pitarch I, Lopez M, Medina J, Povedano M, Fernandez Ramos JA, García MC, Rojas Garcia R, Pascual SI, Málaga I, Eiris J, De Lemus M, Cattinari MG, Cabello R, Diaz P, Terrance M, Maurino J, Rebollo P, Madruga M
	POSC361	EVALUATING THE USE OF TREATMENT PREFERENCE METHODS IN ONCOLOGY CLINICAL TRIALS <b>Disease/disorder: Oncology</b>	Batchelder L, Philpott S, Rodriguez AM

[Click here](#) for further details of posters available on the Virtual ISPOR Europe 2021 website